Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...

Statin use linked to better survival but higher cardiac adverse events in advanced prostate cancer patients treated with ...

Higher BMI statuses were associated with improved survival among patients with prostate cancer, especially those with metastatic disease. Overweight and obesity are associated with improved overall ...